Oxford Brookes University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Oxford United Kingdom (1865)

Organization Overview

First Clinical Trial
2015
NCT02881866
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Oxford Brookes Univeristy | Oxford Brookes University

Active Ingredients

Drugs in Phase 4 Trials (2)

carbamazepine (tegretol) (1 trial)

levetiracetam (keppra) (1 trial)

Drugs in Phase 2 Trials (1)

dapagliflozin (farxiga) (1 trial)

Drugs in Phase 1 Trials (2)

furosemide (lasix) (2 trials)

sodium chloride (1 trial)

Drugs in Other Trials (4)

cocoa bean (1 trial)

glucose (2 trials)

pea protein (2 trials)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 1 (Phase 2)

Dyspnea (Phase 1)

Epilepsy (Phase 4)

Epilepsy, Rolandic (Phase 4)

Hypoglycemia (Phase 2)

Respiratory Aspiration (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 9